Roivant Sciences (ROIV) Form 3 Roivant Sciences / Dan Oren ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Dexcel Pharma Technologies Ltd.

(Last) (First) (Middle)

21 NAHUM HAFTZADI STREET

(Street)

JERUSALEM L3 9548402

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2021

3. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	98,809,158	D(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Dexcel Pharma Technologies Ltd.

(Last) (First) (Middle)

21 NAHUM HAFTZADI STREET

(Street)

JERUSALEM L3 9548402

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Dexxon Holdings Ltd.

(Last) (First) (Middle)

1 DEXCEL STREET

(Street)

OR AKIVA L3 3060000

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Oren Dan

(Last) (First) (Middle)

1 DEXCEL STREET

(Street)

OR AKIVA L3 3060000

(City) (State) (Zip)

Explanation of Responses:

1. Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 643,845 common shares. Dexxon Holdings Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.

	/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman	10/01/2021
	/s/ Dexxon Holdings Ltd. by Dan Oren, Director	10/01/2021
	/s/ Dan Oren	10/01/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.